In the featured article from the February 2017 issue of The Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent—a PET radiotracer—is both safe and effective.
The new agent is a gallium-68 (Ga-68)-labeled peptide BBN-RGD agent that targets both gastrin-releasing peptide receptor (GRPR) and integrin ?v?3. Dual-receptor targeting provides advantages over single-receptor targeting by allowing tumor contrast when either or both receptor types are expressed, improving binding affinity and increasing the number of effective receptors.
Approximately one in seven men will be diagnosed with prostate cancer in his lifetime. In 2017, the American Cancer Society estimates that there will be more than 161,000 new prostate cancer cases in the United States and around 27,000 deaths from the disease. “Although treatable at the early stage, prostate cancer is prone to metastasis,” explain the team of authors, led by Xiaoyuan Chen, senior investigator, Laboratory of Molecular Imaging and Nanomedicine at the U.S. National Institute of Biomedical Imaging and Bioengineering. “An effective and specific imaging method of detecting both primary and metastatic lesions is thus of critical importance to manage patients with prostate cancer.”
This study included 13 patients with prostate cancer (four newly diagnosed and nine post-therapy) and five healthy volunteers. Ga-68-BBN-RGD PET/CT detected 20 bone lesions in seven patients either with primary prostate cancer or after radical prostatectomy. The patients with bone metastases did not necessarily have an elevated prostate specific antigen level. “This result is better than bone scanning with MDP,” Chen notes, referring to the most common radiotracer used today. “MDP bone scans are sensitive but lack specificity because localized skeletal accumulation of Tc-99m-MDP can also be observed in the case of trauma and infection.” No adverse side effects were found during the whole procedure and two-week follow-up, demonstrating the safety of Ga-68-BBN-RGD.
“Compounds capable of targeting more than one biomarker have the ability of binding to both early and metastatic stages of prostate cancer, creating the possibility for a more prompt and accurate diagnostic profile for both primary and the metastatic tumors,” explains Chen.
Looking ahead, Chen says, “Ga-68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.” He points out that larger-scale clinical investigations are warranted.
Learn more: New Type of PET Imaging Identifies Primary and Metastatic Prostate Cancer
[osd_subscribe categories=’prostate-cancer’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “PROSTATE CANCER”‘]
Receive an email update when we add a new PROSTATE CANCER article.
The Latest on: Prostate cancer
[google_news title=”” keyword=”prostate cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Prostate cancer
- ZERO Prostate Cancer Walk/Run helps raise money for survivorson June 2, 2023 at 3:23 pm
ZERO Prostate and Cincinnati Cancer Advisors (CCA) teamed up to not only raise money for research but to also help prostate cancer survivors through education and financial assistance.
- Pluvicto Shortage Regresses Prostate Cancer Careon June 2, 2023 at 2:00 pm
Roby Thomas, MD, the ongoing shortage of the PSMA-targeted radionuclide therapy, Pluvicto and the impact it is having on prostate cancer care.
- AI-driven biomarker predicts optimum length of treatment for prostate canceron June 2, 2023 at 8:08 am
A biomarker developed with digitalized pathology and artificial intelligence demonstrated it was able to identify which men treated with radiation for high-risk localized prostate cancer could be ...
- Personalization May Improve Prostate Cancer Screening Accuracyon June 2, 2023 at 1:50 am
Prostate-specific antigen (PSA) levels are the main biomarker for prostate cancer, and new research has shown how accounting for genetic differences can make PSA screening for cancer more accurate.
- AstraZeneca drug combo gets US nod to treat a type of prostate canceron June 1, 2023 at 12:17 pm
AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant ...
- Accounting for genetic factors can improve accuracy of prostate cancer screeningon June 1, 2023 at 10:18 am
The accuracy of prostate-specific antigen (PSA) screening for prostate cancer can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, ...
- FDA OKs Olaparib-Abiraterone for Metastatic Prostate Canceron June 1, 2023 at 9:46 am
The FDA has approved the PARP inhibitor olaparib (Lynparza) in combination with abiraterone (Zytiga) for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), the ...
- Best Hospitals for Prostate Cancer Surgery in Kansas City, MOon June 1, 2023 at 9:22 am
University of Kansas Hospital in Kansas City, KS is nationally ranked in 8 adult specialties. Read more » Saint Luke's Cancer Institute in Kansas City, MO is nationally ranked in 1 adult specialty.
- Are you truly at risk for prostate cancer? Adding genetics may give more accurate PSA testson June 1, 2023 at 9:03 am
PSA testing can lead to overdiagnosis and missed cancers. It can be improved by adding a man's genetic chance of high or low PSA levels, study finds.
via Bing News